Articles By Jack Cush, MD
faSScinate Study Shows Tocilizumab to be Effective in Systemic Sclerosis
The results of the faSScinate trial were published in Lancet showing that treatment with Actemra (tocilizumab) resulted in a reduction in skin thickness and an improvement in lung function in patients with systemic sclerosis (SSc).
Read Article
Fresolimumab (anti-TGF beta) Improves Systemic Sclerosis
Transforming growth factor (TGF-β) is known to have potent profibrotic activity and has been implicated in the pathogenesis of systemic sclerosis a futile condition with no effective disease modifying treatments.
Read Article
Early DMARD Therapy Averts Cardiovascular Risk in RA
A Finnish early RA register studied 14,878 incident RA patients from 2000-2008 and identified 1157 deaths. Patients receiving DMARDs and MTX had lower mortality rates. The standardized mortality ratio for the entire cohort was reduced (0.57, 95% CI 0.52 to 0.62).
Read Article
10 Ways Rheumatoid Arthritis Could’ve Killed Glenn Frey
I was truly stunned when it was announced that Glenn Frey, from the Eagles, had died as a result of complications from his rheumatoid arthritis, ulcerative colitis and pneumonia.
Read Article
TIPS for Arthritis Travelers
Travel can be challenging for arthritis patients. Here are some useful tips to travel smoothly and pain free.
Read Article
RheumNow Week in Review – 1 July 2016
Dr. Jack Cush reviews highlights from the news and social media in the past week on RheumNow.com
Read Article
Checkpoint Inhibitors Causing Arthritis
A recent report from Johns Hopkins, published in the Annals of Rheumatic Diseases, describes 13 cancer patients treated with the immune checkpoint inhibitors, ipilimumab or nivolumab, who developed inflammatory arthritis and sicca syndrome.
Read Article
Tocilizumab in Pregnancy
Tocilizumab is currently listed as a Category "C" pregnancy risk based on limited pre-clinical (animal) data that was negative.
Read Article
The Brooklyn HAQ
The Health Assessment Questionnaire is a utilitarian outcome measure, often used in clinical trials and daily practice. Unless you’re still prescribing penacillamine, never attended an ACR meeting, and never read an RA clinical trial, you’re quite familiar with the HAQ and its use in practice. So, surely you’ve heard of the “Brooklyn HAQ”?
Read Article
Cancer Risk Lower with TNF inhibitors in Rheumatoid Arthritis
Since the introduction of TNF inhibitors nearly 20 years ago, concerns over a potential associated cancer risk have abounded. The recent ACR RA treatment guidelines have addressed this recently, stating that patients with any solid tumor cancer or risk thereof should be treated as if they ha
Read Article
